BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 11187862)

  • 21. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophilia factor VIII therapy. B- and T-cell tolerance: from basic concepts to clinical practice.
    Saint-Remy JM
    Haematologica; 2000 Oct; 85(10 Suppl):93-6. PubMed ID: 11187884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemophilia treatment. Side effects during immune tolerance induction.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Haematologica; 2000 Oct; 85(10 Suppl):75-7. PubMed ID: 11187878
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
    Landolfi R; de Cristofaro R; Lazzareschi I; Riccardi R; Mariani G
    Haematologica; 2000 Oct; 85(10 Suppl):73-4. PubMed ID: 11187877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regimens of factor VIII administration--continuous infusion vs. bolus.
    Berntorp E
    Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too little.
    Aledort LM
    Semin Thromb Hemost; 2000; 26(2):189-93. PubMed ID: 10919412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological and laboratory aspects of immune tolerance.
    Kazatchkine M; Hoyer L
    Vox Sang; 1996; 70 Suppl 1():52-9. PubMed ID: 8869470
    [No Abstract]   [Full Text] [Related]  

  • 34. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.
    Ewenstein BM; Hoots WK; Lusher JM; DiMichele D; White GC; Adelman B; Nadeau K
    Haematologica; 2000 Oct; 85(10 Suppl):35-9. PubMed ID: 11187868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST; Addiego JE; Reason DC; Lucas AH
    Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune tolerance in hemophilia and treatment of hemophiliacs with an inhibitor.
    Mariani G; Brackmann HH
    Haematologica; 2001 Mar; 86(3):225-6. PubMed ID: 11255267
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hemophilia A with factor VIII inhibitor].
    Shima M
    Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
    [No Abstract]   [Full Text] [Related]  

  • 39. Immune tolerance in two high responder, severe hemophilia A patients with inhibitors: the importance of high doses and the duration of the treatment.
    Ciavarella N; Schiavoni M; Fasano A; Giliberti MG; Ettorre C; Stefanile C
    Vox Sang; 1996; 70 Suppl 1():72-3. PubMed ID: 8869475
    [No Abstract]   [Full Text] [Related]  

  • 40. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.